ONC
Oncternal
Stock
Stock
ISIN: US68236P2065
Ticker: ONCT
US68236P2065
ONCT
Price
Price
CHART BY
Frequently asked questions
What is the Earnings Per Share (EPS) for Oncternal?
Oncternal's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -11.69. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Oncternal's stock?
Currently, 1 analysts cover Oncternal's stock, with a consensus target price of $2.00. Analyst ratings provide insights into the stock's expected performance.
What is Oncternal's revenue over the trailing twelve months?
Over the trailing twelve months, Oncternal reported a revenue of $2.16M.
What is the EBITDA for Oncternal?
Oncternal's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$35.96M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Oncternal?
Oncternal has a free cash flow of -$26.63M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Oncternal have, and what sector and industry does it belong to?
Oncternal employs approximately 27 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Oncternal's shares?
The free float of Oncternal is 2.65M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- EPS (TTM)
- -11.69
- Free Float
- 2.65M
- Revenue (TTM)
- $2.16M
- EBITDA (TTM)
- -$35.96M
- Free Cashflow (TTM)
- -$26.63M
Analyst Ratings
The price target is $2.00 and the stock is covered by 1 analysts.
Buy
0
Hold
1
Sell
0
Information
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
- Employees
- 27
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US68236P2065
- Primary Ticker
- ONCT
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet